Foxy-5 TFA 

Foxy-5 TFA, a WNT5A agonist, is a mimicking peptide of WNT5A which is a non-canonical member of the Wnt family. Foxy-5 TFA triggers cytosolic free calcium signaling without affecting β-catenin activation and it impairs the migration and invasion of epithelial cancer cells. Foxy-5 TFA effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model^[1][2][3].

WNT5A^[2]

Foxy-5 TFA (100 μM, 24 h) inhibits the invasion of tumor cells in DU145 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Foxy-5 TFA (2 mg/kg intraperitoneally injected 9 times a day for 7-23 days) reduces the number of colon cancer stem cells in a mouse model of human colon cancer xenotransplantation^[2].
Foxy-5 TFA (2 mg/kg, intraperitoneal injection, once a day, for 3-9 weeks) significantly reduces the early metastasis and spread of WNT5A low DU145 prostate cancer cells in a mouse model of prostate cancer xenotransplantation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

808.80

C₂₈H₄₃F₃N₆O₁₄S₂

Solid

White to off-white

{For}-Met-Asp-Gly-Cys-Glu-Leu

{For}-MDGCEL

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

• [1]. Säfholm A, et al. The Wnt-5a-derived hexapeptide Foxy-5 inhibits breast cancer metastasis in vivo by targeting cell motility. Clin Cancer Res. 2008 Oct 15;14(20):6556-63.  [Content Brief]

  [2]. Osman J, et al. The WNT5A Agonist Foxy5 Reduces the Number of Colonic Cancer Stem Cells in a Xenograft Mouse Model of Human Colonic Cancer. Anticancer Res. 2019 Apr;39(4):1719-1728.  [Content Brief]

  [3]. Canesin G, et al. Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. PLoS One. 2017 Sep 8;12(9):e0184418.  [Content Brief]